Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of some unusual options trading on Tuesday. Investors bought 13,044 call options on the stock. This represents an increase of approximately 748% compared to the typical daily volume of 1,538 call options.
Insider Activity
In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company's stock in a transaction dated Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the purchase, the insider now owns 7,090,351 shares in the company, valued at $38,004,281.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 12.00% of the company's stock.
Institutional Trading of Capricor Therapeutics
Several large investors have recently made changes to their positions in CAPR. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics during the first quarter worth about $40,000. Main Street Financial Solutions LLC grew its stake in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after purchasing an additional 7,500 shares during the period. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics during the 2nd quarter valued at approximately $147,000. Bank of New York Mellon Corp lifted its stake in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock valued at $381,000 after purchasing an additional 9,040 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Capricor Therapeutics during the second quarter worth $426,000. 21.68% of the stock is owned by hedge funds and other institutional investors.
Capricor Therapeutics Stock Performance
CAPR stock traded down $0.20 during midday trading on Tuesday, reaching $15.01. The stock had a trading volume of 12,833,312 shares, compared to its average volume of 920,410. The firm has a fifty day simple moving average of $5.01 and a two-hundred day simple moving average of $5.36. Capricor Therapeutics has a 52-week low of $2.68 and a 52-week high of $18.14. The stock has a market cap of $480.00 million, a PE ratio of -17.51 and a beta of 3.92.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The firm had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. On average, sell-side analysts predict that Capricor Therapeutics will post -1.14 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms have commented on CAPR. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Tuesday, September 24th. Maxim Group raised their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $8.00 target price on shares of Capricor Therapeutics in a research report on Friday, September 20th. Finally, Oppenheimer reissued an "outperform" rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $22.60.
Check Out Our Latest Research Report on Capricor Therapeutics
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Stories
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
